Mean scores in 14 patients randomized for OPM who requested crossover to treatment by PV 2 weeks after start of the study
| OPM Treatment (n = 14) | After Crossover to PV (n = 14) | Difference OPM–PV | 95% CI Difference | |
|---|---|---|---|---|
| 1 Day | ||||
| VAS for pain (range) | 7.4 (5–10) | 3.9 (0–10) | −3.5 | −4.8–−2.1 |
| Analgesic use (range) | 2.5 (1–3) | 0.9 (0–3) | −1.6 | −2.4–−0.9 |
| 2 Weeks | ||||
| VAS for pain (range) | 6.8 (4–9) | 3.3 (0–7) | −3.5 | −4.9–−2.1 |
| Analgesic use (range) | 2.6 (2–3) | 0.9 (0–3) | −1.7 | −2.5–−1.0 |
| QUALEFFO | 67 | 53 | 14 | 8.5–19 |
| RMD | 18 | 11 | 7 | 2.4–11.4 |
| QUALEFFO subsections | ||||
| Pain | 20 | 13 | −7 | −10.6–−2.6 |
| Function | 13 | 9 | −4 | −5.6–−2.5 |
| Mobility | 20 | 16 | −4 | −6.7–−1.6 |
| Stature | 27 | 22 | −5 | −8.3–−1.6 |
| Social | 26 | 25 | −1 | −3.1–−0.1 |
| Quality of life | 12 | 11 | −1 | −2.1–0.1 |
| Emotion | 32 | 31 | −1 | −2.3–0.2 |
Note:—OPM, optimal pain medication; PV, percutaneous vertebroplasty; CI, confidence interval; VAS, visual analog scale; QUALEFFO, Quality of Life Questionnaire of the European Foundation for Osteoporosis; RMD, Roland-Morris Disability questionnaire.